Encephalomyelitis - Pipeline Review, H2 2019

Published by Global Markets Direct on 11th November 2019 | Ref: 1463984 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Encephalomyelitis - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalomyelitis - Pipeline Review, H2 2019, provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape.

Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Among the common causes of encephalomyelitis are viruses which infect the nervous tissues. Signs and symptoms include neck stiffness, headache, and fever. Treatment includes antibiotics and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalomyelitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Encephalomyelitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalomyelitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Encephalomyelitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalomyelitis (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Encephalomyelitis (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Encephalomyelitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Encephalomyelitis (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Encephalomyelitis (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Encephalomyelitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Encephalomyelitis - Overview

Encephalomyelitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Encephalomyelitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Encephalomyelitis - Companies Involved in Therapeutics Development

AIM ImmunoTech Inc

Aurigene Discovery Technologies Ltd

Biovista Inc

ImmuneBiotech AB

Inflazome Ltd

K-Pax Pharmaceuticals Inc

Philogen SpA

Encephalomyelitis - Drug Profiles

AUR-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-38 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target IL-10, NT-3 and LINGO-1 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IB-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JM-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPAX-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCC-950 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nonathymulin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORNx-KI - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rintatolimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chronic Fatigue Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate NFE2L2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetravil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WEHI-345 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Encephalomyelitis - Dormant Projects

Encephalomyelitis - Product Development Milestones

Featured News & Press Releases

Apr 24, 2018: New Hope for Patients with Mylagic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1463984 | GMDHC11432IDB

Number of Pages

62

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Data
31-05-2019

$2,500 USD

Published by Global Markets Direct
18-03-2019

$2,000 USD

Published by Global Markets Direct
14-08-2018

$2,000 USD

Published by Global Markets Direct
20-02-2018

$2,000 USD

Published by Global Markets Direct
16-08-2017

$2,000 USD

Published by Global Data
11-08-2017

$2,500 USD

Published by Global Markets Direct
15-03-2017

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Encephalomyelitis - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.